...with disease progression on or after chemotherapy. The PDUFA date for the antibody-drug conjugate targeting TF...
...Tissue factorJAK-1 - Janus kinase-1TROP2 (TACSTD2) (EGP-1)- Tumor-associated calcium signal transducer 2 BC Staff Sulopenem etzadroxil-probenecid (PF-03709270) HuMax-TF-ADC...
...tofacitinib extended release Trodelvy, sacituzumab govitecan (hRS7-SN-38, IMMU-132) Iterum Therapeutics plc Seagen Inc. Genmab A/S Pfizer Inc. Gilead Sciences Inc. Tissue factor (TF...

...series B financing led by Lilly Asia Ventures with participation from Loyal Valley Capital, Lanting Capital, TF...

...with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital China, TF...
...$100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital China, TF...

...in-license XB002 (formerly ICON-2) from Iconic Therapeutics Inc. for a $20 million option fee. The TF-targeting...

...RMB800 million ($121.6 million) in a pre-IPO round co-led by Yunfeng Capital, Yingke PE and TF...

...SRL; Maplebrook Ltd.; Full Moon Resources Ltd.; Viktor Pan; Zheng Zhou; Yunfeng Fund III L.P.; TF...

...a series C round to advance its cancer pipeline. The round was co-led by Tigermed, TF...

...syndicate led by CEO Bizuo “Tony” Liu, other undisclosed company executives, Hillhouse Bio Holdings and TF...

...an upfront payment and equity investment. Financial terms were undisclosed. Iconic is developing ICON-4, an anti-TF...
...Btk - Burton's tyrosine kinase; GCGR - Glucagon receptor; GLP-1R (GLP1R) - Glucagon-like peptide-1 receptor; TF...

...listing on NASDAQ Thursday to fuel clinical development and commercialization of antibody-drug conjugate tisotumab vedotin (HuMax-TF-ADC...
...File for IPOs" ). Hongjiang Li, Staff Writer HuMax-TF-ADC, tisotumab vedotin Fulcrum Therapeutics Inc. Genmab A/S Mirum Pharmaceuticals Inc. Tissue factor (TF...